Clinical Evaluation of Montelukast in Veterans With Gulf War Illness

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.
Epistemonikos ID: 0fba0d7bcdafd0b97c01e3c75d2583ced235480b
First added on: Oct 02, 2023